Individual patient data meta-analysis of paclitaxel-coated balloons vs drug-eluting stents for small-vessel coronary artery disease: The ANDROMEDA study
The ANDROMEDA study demonstrated that in patients with de novo small vessel coronary artery disease, treatment with a paclitaxel-coated balloon (PCB) was associated with a lower 3-year risk of major adverse cardiac events (MACE; all-cause death, MI, target lesion thrombosis, and TVR) compared with drug-eluting stents (DES), while no significant difference was observed in target lesion failure (TLF; cardiac death, MI, and TLR), Dr. Simone Fezzi and colleagues, Verona University Hospital, Italy, reported in the May 1 issue of the European Heart Journal.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Recommendations
